For patients with stage III or IV Hodgkin lymphoma, nivolumab with doxorubicin, vinblastine, and dacarbazine (N+AVD) yields ...

An immunotherapy approach to treating advanced Hodgkin lymphoma may drastically increase patients’ chances of survival, ...

The U.S. Food and Drug Administration has approved Itovebi (inavolisib), in combination with palbociclib (Ibrance) and ...

Shares of Jazz Pharmaceuticals are trading only slightly higher in the last few weeks despite two unexpected wins. Explore ...

Discover key gene signatures that could help predict the efficacy of immune checkpoint blockade therapy in patients with ...

Adding nivolumab (Opdivo) instead of brentuximab vedotin (Adcetris) to the standard chemotherapy backbone of doxorubicin ...

US-based Genprex has received approval from the Safety Review Committee (SRC) to proceed to the highest dose group of ...

Jazz Pharmaceuticals announced positive top-line results from the Phase 3 clinical trial evaluating Zepzelca in combination ...

Bank of America Securities analyst Jason Gerberry has reiterated their bullish stance on JAZZ stock, giving a Buy rating today. Jason Gerberry ...

Treatment with cediranib or cediranib plus olaparib is not superior to standard of care (SOC) in patients with platinum-resistant or -refractory epithelial ovarian cancer, according to results from a ...

In mid-2023, the SWOG S1826 phase 3 trial in advanced Hodgkin lymphoma reported highly positive primary results earlier than expected, after the trial’s second planned interim analysis found the ...

NEW YORK, NY / ACCESSWIRE / October 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biodexa Pharmaceuticals Plc ("Biodexa Pharmaceuticals Plc") (NASDAQ:BDRX) ...